NOVOS vs Tally Health: Which Longevity Brand Is Worth It?

The one-sentence version

These two brands look like rivals, but they're really selling different things: NOVOS sells you a once-daily multi-ingredient longevity powder, while Tally Health sells you a number — an at-home epigenetic-age test — wrapped in a coaching membership that points you back toward its own supplement. Pick by which question you're trying to answer, then read the same honest caveat under both: neither has shown, in a human outcome trial, that buying it makes you age slower or live longer. One is a well-reasoned bet on mechanisms; the other is a real piece of population science repackaged as a personal scoreboard. We grade each in depth in our NOVOS review and Tally Health review; this page is the side-by-side.

What each one actually sells

The category confusion starts here, so it's worth being blunt. NOVOS is a product: a daily drink mix bundling roughly a dozen ingredients, each picked to nudge a recognized hallmark of aging. There's no test, no coach, no number — you take it on faith in the formula. Tally Health is a service plus a product: a DNA-methylation cheek-swab test that returns a biological-age estimate, a membership dashboard that tracks that estimate over time, and an own-brand pill the program nudges you toward. One asks you to trust a blend; the other asks you to trust a clock — and then sells you a blend anyway.

That structural difference matters more than any ingredient debate. With NOVOS, you're paying for convenience and a multi-pathway thesis. With Tally, you're paying for measurement first — which sounds more rigorous, until you ask whether the measurement can actually tell you anything actionable.

Grading the evidence, side by side

We hold both to the same bar: separate mechanism from human outcome, and never let a clever design or a famous name stand in for proof. For the full rubric, see how we grade longevity providers.

NOVOS's case is bottom-up. Ingredient A touches senescence, ingredient B touches mitochondria, so the combination "must" slow aging. A couple of components carry genuine but narrow human signals — glycine, as half of the GlyNAC pair, improved oxidative-stress and mitochondrial markers versus placebo in a small older-adult trial¹. But that's biomarker data in a blend that omits glycine's NAC partner, and the rest of the roster is mechanism or animal-grade. Combining individually-plausible ingredients does not produce proven combined efficacy, and no trial has tested the finished NOVOS product against placebo on a real outcome.

Tally's case is top-down. The epigenetic clock underneath is legitimate population science — methylation-age testing predicts mortality across large cohorts², and the most credible pace-of-aging clock was even slowed by a randomized caloric-restriction intervention in the CALERIE trial³. That's a stronger evidentiary foundation than anything in NOVOS's jar. The catch is what that science licenses: predicting outcomes across thousands of people is a different claim from telling one buyer whether a protocol moved their personal risk. No clock has been validated as a modifiable individual target, and single-test reproducibility noise can rival the change a short routine produces.

So the two land in different failure modes. NOVOS is a thoughtful formula with thin human proof. Tally is real science aimed at a use case it hasn't been validated for — and it bundles a supplement that faces the exact same "no human outcome trial" wall NOVOS does.

The testing component — Tally's real differentiator

This is the one thing NOVOS doesn't offer, and it's worth weighing honestly. A biological-age readout is seductive: a single number that feels like a verdict on how you're aging. Used once, as a soft risk signal from a credible brand, it's a defensible curiosity. The trouble is the membership model, which encourages you to retest every few months to "watch your number drop" — precisely the use case the evidence doesn't support, because an apparent improvement may be measurement wobble rather than biology. And when the same company sells both the test and the pill meant to improve it, an unvalidated readout quietly becomes a sales tool. If a measured biological-age number is what you're after, a free blood-based PhenoAge calculator and the tools we maintain get you a comparable signal without the subscription.

Cost, and who each suits

Both sit in shifting DTC pricing territory — treat any figure as current market info. NOVOS runs roughly $50–$100/month for the supplement alone. Tally spans a one-off test in the low hundreds up to a recurring membership bundling retests, coaching, and supplement discounts, so it's typically the bigger commitment once you're inside the membership funnel.

• •Lean toward NOVOS if you want one convenient multi-pathway formula instead of ten separate jars, you've read the evidence, and you're comfortable paying for a mechanism-level bet without expecting a measurable result.
• •Lean toward Tally if your real itch is curiosity about a one-time epigenetic snapshot from a credible founder — and you'll read the number as a soft signal, skip the obsessive retesting, and not reorganize your spending around the Vitality subscription.
• •Skip both if you're expecting either to demonstrably slow your aging. The boring proven levers — exercise, sleep, treating blood pressure and metabolic disease — do more for lifespan than either purchase, and they're free.

For a broader view of what's actually worth buying in this category, see our best longevity supplements roundup, and for a testing-first brand graded the same way, our Superpower Health review.

Bottom line

NOVOS and Tally Health aren't really competitors — they answer different questions. NOVOS is the more thoughtfully-formulated product, with a defensible multi-pathway design and one or two narrow human biomarker signals, but zero outcome proof on the finished blend. Tally is built on the more legitimate science — epigenetic clocks are real population biology — but it sells that science as a personal scoreboard it hasn't earned, and routes you toward a supplement with no more human longevity proof than NOVOS's. If you want a convenient mechanism bet, NOVOS edges it on honesty-of-purpose. If you want a one-time number from a credible name, Tally's test is the draw — just don't pay for the subscription that turns an unvalidated readout into a sales loop. Read both full grades first: our NOVOS review and Tally Health review.